Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Short term Debt (2024 - 2025)

Caris Life Sciences (CAI) has 2 years of Short term Debt data on record, last reported at $169000.0 in Q4 2025.

  • For Q4 2025, Short term Debt fell 99.72% year-over-year to $169000.0; the TTM value through Dec 2025 reached $169000.0, down 99.72%, while the annual FY2025 figure was $169000.0, 99.72% down from the prior year.
  • Short term Debt reached $169000.0 in Q4 2025 per CAI's latest filing, up from $164000.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $60.1 million in Q4 2024 and bottomed at $95000.0 in Q2 2025.